

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 3366207, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 7, 2005

Signature:

Georgina Matos
(Georgina Matos)

JCO3 Rec'd PCT/PTO 07 APR 2005 #4
(1604)


PTO-1390 (Rev. 02-2005)

Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 254082000100
INTERNATIONAL APPLICATION NO. PCT/IL03/00312	INTERNATIONAL FILING DATE 15 April 2003	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/512,024
PRIORITY DATE CLAIMED 19 April 2002		
TITLE OF INVENTION β-AGONIST COMPOUNDS COMPRISING NITRIC OXIDE DONOR GROUPS AND REACTIVE OXYGEN SPECIES SCAVENGER GROUPS AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISORDERS		
APPLICANT(S) FOR DO/EO/US Abdullah I. HAJ-YEHIA		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none">1. <input type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371 (f)). The submission must include items (5), (6), (9) and (21) indicated below.4. <input type="checkbox"/> The US has been elected (Article 31).5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c)(2))<ol style="list-style-type: none">a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> has been communicated by the International Bureau.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).<ol style="list-style-type: none">a. <input type="checkbox"/> is attached hereto.b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))<ol style="list-style-type: none">a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> have been communicated by the International Bureau.c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input type="checkbox"/> have not been made and will not be made.8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).		
Items 11 to 20 below concern document(s) or information included:		
<ol style="list-style-type: none">11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages)12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.13. <input type="checkbox"/> A preliminary amendment.14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.15. <input type="checkbox"/> A substitute specification.16. <input type="checkbox"/> A power of attorney and/or change of address letter.17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).20. <input checked="" type="checkbox"/> Other items or information: Form PTO/SB/08a/b + copy (6 pages); 49 References; and Return Receipt Postcard		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/512,024		INTERNATIONAL APPLICATION NO. PCT/IL03/00312		ATTORNEY'S DOCKET NUMBER 254082000100	
The following fees have been submitted				CALCULATIONS	PTO USE ONLY
21. <input type="checkbox"/> Basic national fee \$300				\$ 0.00	
22. <input type="checkbox"/> Examination fee				0.00	
If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) \$100					
All other situations \$200				\$ 0.00	
23. <input type="checkbox"/> Search fee					
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$100					
International Search Report prepared and provided to the Office \$400					
All other situations \$500				\$ 0.00	
TOTAL OF 21, 22 and 23 =				\$ 0.00	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
105 - 100 =	5 /50 =	1	x \$250.00	0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$ 0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	117 - 117 =	0	x 18.00	\$ 0.00	
Independent claims	5 - 5 =	0	x 88.00	\$ 0.00	
MULTIPLE DEPENDENT CLAIM(s) (if applicable)			+ 300.00	\$ 0.00	
TOTAL OF ABOVE CALCULATIONS =				\$ 0.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.				\$ 0.00	
SUBTOTAL =				\$ 0.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$ 0.00	
TOTAL NATIONAL FEE =				\$ 0.00	
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$ 0.00	
TOTAL FEES ENCLOSED =				\$ 0.00	
				Amount to be refunded:	\$0.00
				Amount to be charged:	\$0.00
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. <u>03-1952</u> in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>03-1952</u>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p> <p>NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the International Application to pending status.</p> <p>SEND ALL CORRESPONDENCE TO:</p> <p style="text-align: right;">SIGNATURE:  NAME: <u>Kimberly A. Bolin</u></p> <p>CUSTOMER NUMBER: 25226</p> <p style="text-align: right;">REGISTRATION NUMBER: <u>44,546</u></p>					

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 336620769 US, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 7, 2005

Signature: 

(Georgia Matos)

Patent

Docket No. 254082000100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Abdullah I. HAJ-YEHIA

Serial No.: 10/512,024

Int'l Appl No.: PCT/IL03/00312

Int'l Filing Date: April 15, 2003

For: β -AGONIST COMPOUNDS
COMPRISING NITRIC OXIDE DONOR
GROUPS AND REACTIVE OXYGEN
SPECIES SCAVENGER GROUPS AND
THEIR USE IN THE TREATMENT OF
RESPIRATORY DISORDERS

Examiner: Not Yet Assigned

Group Art Unit: 1626

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;
or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 254082000100.

Dated: April 7, 2005

Respectfully submitted,

By 

Kimberly A. Bolin
Registration No.: 44,546
MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-5740

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/512,024
				Filing Date (Int'l)	April 15, 2003
				First Named Inventor	Abdullah I. HAJ-YEHIA
				Art Unit	1626
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	254082000100

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-2001/0041190-A1	11-15-2001	Ward et al.	
	2.	US-2002/0006901-A1	01-17-2002	Iacono	
	3.	US-2002/0034477-A1	03-21-2002	Edwards et al.	
	4.	US-2004/0147598-A1	07-29-2004	Haj-Yehia	
	5.	US-RE 37,116-E	03-27-2001	Garvey et al.	
	6.	US-4,166,452	09-04-1979	Generales Jr.	
	7.	US-4,256,108	03-17-1981	Theeuwes	
	8.	US-4,265,874	05-05-1981	Bonsen et al.	
	9.	US-4,992,474	02-12-1991	Skidmore et al.	
	10.	US-5,277,195-A	01-11-1994	Williams	
	11.	US-5,320,094-A	06-14-1994	Laube et al.	
	12.	US-5,327,883-A	07-12-1994	Williams et al.	
	13.	US-5,364,833-A	11-15-1994	Kast et al.	
	14.	US-5,364,838-A	11-15-1994	Rubsamen	
	15.	US-5,404,871-A	04-11-1995	Goodman et al.	
	16.	US-5,419,315-A	05-30-1995	Rubsamen	
	17.	US-5,492,112-A	02-20-1996	Mecikalski et al.	
	18.	US-5,506,203-A	04-09-1996	Bäckström et al.	
	19.	US-5,518,998-A	05-21-1996	Bäckström et al.	
	20.	US-5,558,085-A	09-24-1996	Rubsamen et al.	
	21.	US-5,577,497-A	11-26-1996	Mecikalski et al.	
	22.	US-5,622,166-A	04-22-1997	Eisele et al.	
	23.	US-5,645,051-A	07-08-1997	Schultz et al.	
	24.	US-5,654,007-A	08-05-1997	Johnson et al.	
	25.	US-5,655,523-A	08-12-1997	Hodson et al.	
	26.	US-5,658,878-A	08-19-1997	Bäckström et al.	
	27.	US-5,661,130-A	08-26-1997	Meezan et al.	
	28.	US-5,672,581-A	09-30-1997	Rubsamen et al.	
	29.	US-5,700,904-A	12-23-1997	Baker et al.	
	30.	US-5,743,250-A	04-28-1998	Gonda et al.	
	31.	US-5,780,014-A	07-14-1998	Eljamal et al.	
	32.	US-5,821,259-A	10-13-1998	Theoharides	
	33.	US-5,824,669-A	10-20-1998	Garvey et al.	
	34.	US-6,060,069-A	05-09-2000	Hill et al.	
	35.	US-6,083,993-A	07-04-2000	Barberich et al.	
	36.	US-6,124,319-A	09-26-2000	MacCoss et al.	
	37.	US-6,232,331-B1	05-15-2001	Sankaranarayanan	
	38.	US-6,238,647-B1	05-29-2001	Akehurst et al.	
	39.	US-6,241,969-B1	06-05-2001	Saidi et al.	
	40.	US-6,248,895-B1	06-19-2001	Sankaranarayanan	
	41.	US-6,254,882-B1	07-03-2001	Jerussi	
	42.	US-6,297,762-B1	10-02-2001	Labitt	
	43.	US-6,299,863-B1	10-09-2001	Aberg et al.	
	44.	US-6,335,316-B1	01-01-2002	Hughes et al.	
	45.	US-6,369,071-B1	04-09-2002	Haj-Yehia	
	46.	US-6,448,267-B1	09-10-2002	Anggard et al.	
	47.	US-6,455,542-B1	09-24-2002	Anggard et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/512,024
				Filing Date (Int'l)	April 15, 2003
				First Named Inventor	Abdullah I. HAJ-YEHIA
				Art Unit	1626
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	254082000100

48.	US-6,492,405-B2	12-10-2002	Haj-Yehia	
49.	US-6,642,260-B2	11-04-2003	Haj-Yehia	
50.	US-6,759,430-B2	07-06-2004	Anggard et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code ² -Number ³ -Kind Code ⁴ (if known)					
	51.	AU-733202-B2		10-10-1997	NitroMed Inc.		
	52.	GB-2 349 385-A		11-01-2000	Teijin Limited		
	53.	WO-95/24183-A1		09-14-1995	Inhale Therapeutic Systems		
	54.	WO-95/30641-A1		11-16-1995	Nicox Ltd.		
	55.	WO-96/32149-A1		10-17-1996	Inhale Therapeutic Systems		
	56.	WO-96/32946-A1		10-24-1996	Nitromed Inc.		
	57.	WO-96/39409-A1		12-12-1996	Nitromed Inc.		
	58.	WO-97/25984-A1		07-24-1997	Schering Aktiengesellschaft et al.		
	59.	WO-97/31654-A1		09-04-1997	Nicox S.A.		
	60.	WO-97/34871-A1		09-25-1997	Nitromed Inc.		
	61.	WO-98/33480-A1		08-06-1998	Aradigm Corp.		
	62.	WO-98/42661-A1		10-01-1998	Yissum Research Dev.		
	63.	WO-98/55453-A1		12-10-1998	Medinox, Inc.		
	64.	WO-99/37616-A1		07-29-1999	Anggard et al.		
	65.	WO-99/40787-A1		08-19-1999	Medinox Inc.		
	66.	WO-99/61018-A1		12-02-1999	Sankaranarayanan		
	67.	WO-99/61430-A1		12-02-1999	Sankaranarayanan		
	68.	WO-99/62509-A1		12-09-1999	Nitromed Inc.		
	69.	WO-99/66918-A1		12-29-1999	Medinox Inc.		
	70.	WO-00/31060-A1		06-02-2000	Yissum Research Dev.		
	71.	WO-00/35434-A2, A3		06-22-2000	Cellegy Pharmaceuticals Inc.		
	72.	WO-00/53191-A2, A3		09-14-2000	The University of Manitoba		
	73.	WO-00/67754-A1		11-16-2000	Nitromed Inc.		
	74.	WO-01/32202-A1		05-10-2001	AGA AB		
	75.	WO-03/088961-A1		10-30-2003	Yissum Research Dev.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	76.	Anonymous (November 3, 1990). "Editorials: β 2 Agonists in Asthma: Relief, Prevention, Morbidity," <i>Lancet</i> 336(8723):1411-1412.		
	77.	Boushey, H.A. (1998). "Bronchodilators & Other Agents Used in Asthma," Chapter 20 <i>In Basic & Clinical Pharmacology</i> Seventh Edition, Katzung, B.G. ed. Appleton and Lange: Stamford, CT pp. 325-342.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

pa-965933

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/512,024
				Filing Date (Int'l)	April 15, 2003
				First Named Inventor	Abdullah I. HAJ-YEHIA
				Art Unit	1626
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	254082000100

78.	Burrows, B. et al. (February 20, 1992). "The β -Agonist Dilemma," <i>The New England Journal of Medicine</i> 326(8):560-561.
79.	Costello, J.F. ed. (1997). <i>Sympathomimetic Enantiomers in the Treatment of Asthma</i> The Parthenon Publishing Group, Inc.: London. (Table of Contents Only.)
80.	Cotran, R.S. et al. (1989). "The Respiratory System" Chapter 16 <i>In Robbins Pathologic Basis of Disease</i> Fourth Edition, W.B. Saunders Co.: Philadelphia, PA pp. 755-797.
81.	Haahtela, T. et al. (August 8, 1991). "Comparison of a B2-Agonist, Terbutaline, With an Inhaled Corticosteroid, Budesonide, in Newly Detected Asthma," <i>The New England Journal of Medicine</i> 325(6):388-392.
82.	Haj-Yehia, A. et al. (July/August 2000). "Development of 3-Nitratomethyl-PROXYL (NMP): A Novel, Bifunctional Superoxide Dismutase-Mimic-Nitric Oxide-Donor," <i>Drug Development Research</i> 50(3/4):528-536.
83.	Hansel, T. et al. ed. (2001). <i>New Drugs for Asthma, Allergy and COPD</i> Karger: London, Vol. 31, pp. v-vii (Table of Contents Only.)
84.	Hett, R. et al. (1994). "Enantioselective Synthesis of Salmeterol via Asymmetric Borane Reduction," <i>Tetrahedron Letters</i> 35(50):9375-9378.
85.	Hett, R. et al. (1997). "Enantio- and Diastereoselective Synthesis of all Four Stereoisomers of Formoterol," <i>Tetrahedron Letters</i> 38(7):1125-1128.
86.	Hoffman, B.B. (1998). "Adrenoceptor-Activating & Other Sympathomimetic Drugs," Chapter 9 <i>In Basic & Clinical Pharmacology</i> Seventh Edition, Katzung, B.G. ed. Appleton and Lange: Stamford, CT pp. 118-151.
87.	Jansen, A. et al. (1992). "The Relaxant Properties in Guinea Pig Airways of S-Nitrosothiols," <i>J. Pharmacol. Exptl. Therapeutics</i> 261(1):154-160.
88.	Kaminsky, D.A. et al. (October 1999). "Nitrotyrosine Formation in the Airways and Lung Parenchyma of Patients with Asthma," <i>J. Allergy Clin. Immunol.</i> 104(4/1):747-754.
89.	Murray, J.F. et al. eds. (October-November 1979). <i>American Review of Respiratory Disease</i> 120(4/5) (Table of Contents Only.)
90.	Rees, J. (May 18, 1991). "B2 Agonists and Asthma," <i>British Medical Journal</i> 302(6786):1166-1167.
91.	Robak, J. et al. (1993). "Nitric Oxide Donors as Generators and Scavengers of Superoxide Anions," <i>Pol. J. Pharmacol.</i> 45(1):51-58.
92.	Robak, J. et al. (December 20, 1993). "Nitric Oxide Donors as Generators and Scavengers of Superoxide Anions," <i>Chemical Abstracts</i> 25:71 Abstract No. 119:262465b.
93.	Shiraishi, M. et al. (October 14, 1996). "Drugs for Improvement of Lipid Metabolism," <i>Chemical Abstracts</i> 125(16):649 Abstract No. 125:204523g.
94.	Spitzer, W.O et al. (February 20, 1992). "The Use of β -Agonists and the Risk of Death and Near Death From Asthma," <i>The New England Journal of Medicine</i> 326(8):501-506.
95.	Svedmyr, N. et al. (1990). "The Current Place of β 2-Agonists in the Management of Asthma," <i>Lung</i> 168(Supp):105-110.
96.	Tamaoki, J. et al. (June 1995). "Role of NO Generation in β -Adrenoceptor-Mediated Stimulation of Rabbit Airway Ciliary Motility," <i>Am. J. Physiol.</i> 268(6):C1342-C1346.
97.	Thompson, R.F. et al. (July-August 1985). "Hypersensitivity Vasculitis Associated With Streptokinase," <i>Clin. Pharm.</i> 4(4):383-386.
98.	Wagner, A.F. et al. (October 5, 1956). "Properties and Derivatives of α -Lipoic Acid," <i>Journal of the American Chemical Society</i> 78:5079-5081.
99.	Wolf, E.W. et al. (1998). "Reversal of Cerebral Vasospasm Using an Intrathecally Administered Nitric Oxide Donor," <i>J. Neurosurg.</i> 89(2):279-288.

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

pa- 965933